Stockreport

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

OnKure Therapeutics, Inc. - Class A  (OKUR) 
PDF — PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging prelim [Read more]